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Objective: Evidence supports an important role for miR-203 in the regulation of the proliferation, migration and
invasion of prostate cancer (PCa) cells. However, the exact mechanisms of miR-203 in PCa are not entirely clear.
Methods: We examined the expression of miR-203 in prostate cancer tissues, adjacent normal tissues, PCa cell lines
and normal prostate epithelial cells by qRT-PCR. Then, the effects of miR-203 or Rap1A on proliferation, adhesion
and invasion of PCa cells were assayed using CKK-8, adhesion analysis, and transwell invasion assays. Luciferase reporter
assay was performed to assess miR-203 binding to Rap1A mRNA. Tumor growth was assessed by subcutaneous
inoculation of cells into BALB/c nude mice.
Results: Here, we confirmed that the expression of miR-203 was significantly downregulated in prostate cancer
specimens compared with matched adjacent normal prostate specimens. Mechanistic dissection revealed that
miR-203 mediated cell proliferation, adhesion and invasion in vitro, and tumor growth in vivo, as evidenced by
reduced RAC1, p-PAK1, and p-MEK1 expression. In addition, we identified Rap1A as a direct target suppressed by
miR-203, and there was an inverse relationship between the expression of miR-203 and Rap1A in PCa. Knockdown
of Rap1A phenocopied the effects of miR-203 on PCa cell growth and invasion. Furthermore, Rap1A over-
expression in PCa cells partially reversed the effects of miR-203-expression on cell adhesion and invasion.
Conclusions: These findings provide further evidence that a crucial role for miR-203 in inhibiting metastasis of PCa
through the suppression of Rap1A expression.
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Prostate cancer is the most frequent malignancy among
men in most developed countries, and it was estimated
to contribute to 28% of newly diagnosed cancers and
11% of cancer-related deaths in 2011 [1]. The progression-
free survival rates are so short due to limited treatment
strategies, which include surgery, radiation therapy and
new therapeutic agents [2,3]. Although the etiology of
prostate cancer is still unknown, growing evidence has in-
dicated that multiple changes in specific genes in particu-
lar tumors are responsible for the development and
progression of PCa [4-7]. There is an urgent need for new,* Correspondence: wudeng123long@163.com
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in clinical applications.
MicroRNAs (miRNAs) are endogenous small non-
coding RNAs of 18–25 nucleotides that act as posttran-
scriptional regulators of gene expression in diverse bio-
logical processes through imperfect base pairing with
the 3′-UTR of target mRNAs, inhibiting target gene ex-
pression [8,9]. More interestingly, the roles of miRNA
have proven to be indispensable in affecting cancer biol-
ogy, including proliferation, autophagy, apoptosis, and
invasiveness [10-14]. Accumulating data have suggested
that miRNAs are involved in the tumorigenesis and pro-
gression of prostate cancer and act as a tumor suppres-
sors or oncogenes [15-20]. MiR-203, a putative tumor
suppressor gene, has been shown to inhibit cell prolifer-
ation and invasion and modulate the chemotherapyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cer cells, glioma cells, and breast cancer cells [21-24].
At first, miR-203 has been identified as a skin-specific
microRNA, and altering expression of miR-203 in vivo
results in promoting epidermal differentiation by
restricting proliferative potential and inducing cell-cycle
exit through targetting p63, an essential regulator of
stem cell maintenance in epithelial stratified tissues
[25]. It has been reported that in breast cancer miR203
targets SOCS3 (suppressor of cytokine signaling 3), a
negative regulator of fetal liver hematopoiesis and placen-
tal development, and ABL1 (Abelson murine leukemia
viral oncogene homolog 1), which implicates in processes
of cell differentiation, cell division, cell adhesion, and
stress response [26,27]. More importantly, miR-203 ex-
pression was also observed to be downregulated in pros-
tate cancer tissues, and the over-expression of miR-203
significantly suppresses the growth and invasion of PCa
cells [28-30]. Therefore, further exploring the function of
miR-203 could broaden the strategies for prostate cancer
treatment.
According to the mRNA sequence, Rap1A (Ras-related
protein Rap-1A), member of RAS oncogene family, is a
predicted target of miR-133a, which shares approxi-
mately 50% amino acid identity with the classical RAS
proteins and has numerous structural features in com-
mon [31]. Researches in leukocytes first demonstrated
that Rap1 can enhance cell adhesion and migration and
activate survival pathways [32,33]. RAP1 has been indi-
cated to activate the MAPK/ERK pathway, which can
contribute cell migration and inhibit cell differentiation
[34,35]. In lung cancer, knocking down Rap1A can
sensitize cancer cells to chemotherapy [36]. It is also re-
ported that activation of rap1promotes metastasis in
prostate cancer and pancreatic cancer [37].
The purpose of the present study was to verify the
expression of miR-203 and investigate the molecular
mechanisms through which it inhibits tumor growth
and metastasis. Our data proved that Rap1A is a direct
target of miR-203 and over-expression of Rap1A partly
rescue the effect of miR-203 on cell proliferation, adhe-
sion and invasion. All these indicate that miR-203
functions as tumor suppresser through inhibiting
Rap1A in PCa and miR-203 may be used in clinical ap-
plications for cancer.
Methods
Cell lines and cultures
Human prostate cancer cell lines (22Rv1, LNCaP, PC3,
DU 145), human HEK293T cells and nonmalignant epi-
thelial prostate cell lines RWPE-1 were purchased from
the American Tissue Culture Collection (ATCC) and
were cultured in growth medium and under conditions
recommended by the supplier.Clinical samples
Paired tumorous and adjacent non-tumorous prostate
tissues from 53 prostate cancer patients were obtained
from the Tongji Hospital Subordinated to Tongji
University with prior approval by the Ethics Committee
of Tongji University and conducted according to the
Declaration of Helsinki. The clinical diagnosis was made
by a pathologist and confirmed by hematoxylin and
eosin (H&E) staining. Surgical specimens used in this
study were radical prostatectomy specimens and se-
lected from the frozen prostate tumor bank if paired
frozen blocks enriched for histologically normal and
tumor areas were available.
RNA isolation and quantitative real-time PCR (qRT-PCR)
RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) from prostate tissues and cells fol-
lowing the manufacturer’s protocol. The quantification
of isolated RNA was assessed by a NanoDrop 2000 spec-
trophotometer (Nanodrop Technology, Inc., Wilmington,
DE). Small RNA was converted to complimentary DNA
using poly-A polymerase-based PrimeScript™ miRNA
qPCR Starter Kit (TaKaRa). Approximately 500 ng total
RNA was converted to cDNA using a PrimeScript™ One
Step RT-PCR Kit (TaKaRa). Real-time qPCR was per-
formed on the ABI Prism 7900HT (Applied Biosystems,
Life Technologies, CA) using SYBR Green (TaKaRa) ac-
cording to the manufacturer’s instructions. Small nu-
clear RNA U6 was used as an internal control for miR-
203 and GAPDH was used to normalize Rap1A. Primers
used for quantification were as follows: (Rap1A forward
primer, 5′-GAAGAACGGCCAAGGTTTTGC-3′; Rap1A
reverse primers, 5′-CCGTGTCCTTAACCCGTAAAATC-
3′; GAPDH forward primer, 5′-GAAGGTGAAGGTCGG
AGTC-3′; GAPDH reverse primers, 5′-GAAGATGGTG
ATGGGATTTC-3′). Each sample was run in three repli-
cates with a dissociation curve analysis.
Plasmid constructs
To construct the has-miR-203 expression vector, the se-
quence containing the miR-203 pre-miRNA was ampli-
fied by PCR from human genomic DNA using the
forward primer 5′-AAATCTAGACCAGGCGAGGGC
GTCTAA-3′ and the reverse primer 5′-AAAAGAATTC
AGCGGTTCCCACAGCACA-3′. The final PCR prod-
uct was cloned into the XbaI/EcoRI sites of the pCDH-
CMV-EF1-copGFP vector (SBI) according to the manu-
facturer’s instructions and named pCDH-miR-203.
A 555-bp fragment of the coding sequence of human
Rap1A was amplified by RT-PCR using specific primers
sense 5′-AAAGGATCCTATGCGTGAGTACAAGCTAG
TGGT-3′ and anti-sense 5′-AAAAGAATTCCTAGAGC
AGCAGACATGATTTCT-3′ and cloned into pCDNA3.1
(+) vector (Invitrogen) and named it pCDNA- Rap1A.
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the full-length 3′-UTR of Rap1A was subcloned into the
pMIR-REPORT™ Luciferase (Lifetechnologies) to gener-
ate RAP1A-3′-UTR-WT. A mutant construct of Rap1A
3′-UTR, named RAP1A-3′-UTR-MUT, which carried a
substitution of four nucleotides within the predicted
miR-203 binding sites of Rap1A 3′-UTR, was carried
out using a Phusion® site-directed mutagenesis kit (New
England Biolabs). The primers for Rap1A 3′-UTR were
5′-AAAAAGCTTGCCCATAGTCAGCAGCAGCT −3′
and the reverse primer was 5′-AAAACGGCTTACAAG
CTGTGGAAGATCTGAAATA −3′.
To knockdown Rap1A in the PC-3 and DU145 cell
lines, oligonucleotides targeting Rap1A were designed and
annealed to clone into the pLKO.1-TRC cloning vector at
the AgeI/EcoRI sites with the forward primer 5′-CCG
GCCCAACGATAGAAGATTCCTACTCGAGTAGGAA
TCTTCTATCGTTGGGTTTTTG-3′ and the reverse pri-
mer 5′-AATTCAAAAACCCAACGATAGAAGATTCCT
ACTCGAGTAGGAATCTTCTATCGTTGGG-3′. The
scramble vector (SCR) was used as negative control.
All sequences of plasmids were confirmed by DNA
sequencing.
Generation of stable cell lines
The lentiviruses were produced by co-transfecting
HEK293T according to the manufacturer’s instructions.
For over-expression studies, the lentiviruses expressing
miR-203 and control viruses expressing GFP were used
to infect PC-3 and DU145 cell lines in the presence of
4 g/ml of polybrene (Sigma). The efficacy of miR-203
over-expression was assessed by qRT-PCR. For Rap1A
silencing, PC-3 and DU 145 cell lines were infected as
described above for miR-203. Puromycin (4 μg/ml)
(Sigma-Aldrich, St. Louis, MO) was added 2 days after
infection for the selection of infected cells. Western
blots were performed to detect the efficiency of Rap1A
in the selected cells.
Luciferase assays and transient transfections
HEK 293 T cells were co-transfected with 1 μg of
RAP1A-3′-UTR-WT or RAP1A-3′-UTR-MUT plasmid
and 50 ng of pRL-TK Renilla luciferase expression plas-
mid with an empty vector control or pCDH-miR-203
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). Approximately 24 hours after transfection, cells
were lysed, and luciferase activity was determined on a
scintillation counter with the Dual-Luciferase reporter
assay system (Promega). Firefly luciferase activity was
normalized to Renilla luciferase activity for each sample.
PC-3 and DU 145 cells overexpressed miR-203 were
transfected with Anti-miRNA inhibitors Negative Con-
trol (anti-NC) and anti-miR-203 inhibitor (anti-miR-203)
(Applied Biosystems) at a final concentration of 50 nMwith the Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s instructions. Each reporter plasmid was trans-
fected at least three times and each sample was assayed
in triplicate.
Cell proliferation assay
Approximately 4 × 103 cells per well in triplicate were
seeded in 96-well plates. Cell proliferation assays were
assessed at 24, 48 and 72 hours using Cell Counting Kit-8
(CKK-8) (Dojindo, Rockville, MD). The relative number of
cells was determined by measuring the optical density of
each sample at 450 nm in a microplate reader (Beckman
Coulter DTX880 Multimode Detector). All experiments
were performed three times, and the average results were
calculated.
Cell adhesion and invasion assay
Approximately 1 × 105 cells were harvested and resus-
pended in culture medium and then transferred to a
24-well plate that was coated with matrix proteins
(40 μg/ml type I collagen or 2 μg/cm2 fibronectin in
PBS) at room temperature for 1 h and washed twice
with phosphate-buffered saline (PBS) to remove the
non-adherent cells. The attached cells were measured
by CCK-8 in a microplate reader at 450 nm. The adhe-
sion of cells was related to the control set at 100%.
The cells (2 × 105/well) were suspended in 100 μl of
serum-free medium and placed into the upper chamber
of the insert with an 8-μm micro-porous membrane
(Costar, Corning Inc., MA) coated with Matrigel (BD
Bioscience, Bedford, MA). Medium containing 20% fetal
bovine serum was added into the lower chamber. Follow-
ing 24 hours of incubation at 37°C, the cells remaining on
the upper surface of the membrane were removed with a
cotton swab, and the migrated cells on the lower surface
were fixed with methanol and stained with 1% crystal vio-
let for 15 minutes. The stained cells were counted in five
randomly selected fields per membrane under an inverted
Olympus phase-contrast microscope (100× magnifica-
tion). Each experiment was performed in triplicate wells
and repeated three times.
Western blot analysis
Total cellular and tissue proteins were lysed in RIPA buf-
fer in the presence of protease inhibitors (Roche Applied
Science, Mannheim, Germany). Protein concentration was
quantified using the Bio-Rad Protein Assay Kit (Bio-Rad
Laboratories, Hercules, CA). Equivalent protein (50 ug)
from each sample was loaded, and the lysates were sepa-
rated by SDS–PAGE electrophoresis and transferred to a
PVDF membrane (Bio-Rad Laboratories, Hercules, CA).
Membranes were blocked in 5% milk in Tris-buffered sa-
line (TBST) containing 0.5% Tween-20 for 1 hour and
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p-MEK1, p-PAK1, GAPDH, Cell Signaling Technology;
MEK1, PAK1, OriGene Technologies) overnight at 4°C.
After 3 washes (10 min) in TBST, membranes were de-
tected using horseradish peroxidase-linked goat anti-
mouse or goat anti-rabbit IgG antibodies and visualized
with the SuperSignal chemiluminescent system (Thermo
Scientific, Rockford, IL). The intensity of the bands was
analyzed using Bandscan software. All the shown images
are from a single experiment that is representative of at
least three separate experiments.
Tumor Xenografts in vivo
Mice were maintained in the animal facility and all experi-
mental procedures using animals were approved by the
Institutional Animal Care and Use Committee of Tongji
University. DU 145 cells infected with vector or miR-203
at 5 × 106 cells/150 μl were injected subcutaneously into
the left flanks of anesthetized 6-week-old NOD-SCID
mice. Mice were sacrificed 5 weeks later and tumor weight
was determined in grams at the end of the experiment.
Tumor samples were excised for western blotting.
Statistical analysis
All data were presented as the means ± S.D of three or
more replications. For relative gene expression, paired
Student’s t test was used to determine the statistical sig-
nificance and two-tailed unpaired Student’s t tests and
analysis of variance were used for statistical evaluation
of the data. Pearson's correlation analysis was performed
to examine the correlation between miR-203 and Rap1AFigure 1 Expression of miR-203 in PCa samples and cell lines. (A) The
matched adjacent normal tissues. (B) The miR-203 expression level was de
expression of miR-203 was analyzed in 22Rv1, LNCaP, PC3, DU 145 cells an
qRT-PCR and normalized with an endogenous control (U6). * p < 0.05, ** pmRNA levels of human PCa tissues. Data analysis was
performed using GraphPad Prism 4.0 (Graph Pad Software,
La Jolla, CA) and two-tailed p values < 0.05 were consid-
ered to be significant.
Results
MiR-203 is aberrantly expressed in human prostate
cancer tissues and cell lines
Previous reports have shown that miR-203 was reduced
in primary prostate cancer and even more reduced in
metastatic PCa. To further confirm the expression of
miR-203, especially among Chinese patients, we ex-
tended our sample to 53 pairs of clinical specimens. We
found that miR-203 was significantly down-regulated in
carcinoma tissues compared with the matched adjacent
non-tumor tissues (P < 0.01; Figure 1A). Furthermore, in
comparison to primary tumors tissues with lymph node
and/or bone metastasis, miR-203 levels were signifi-
cantly lower in PCa tissues without metastasis (P < 0.05;
Figure 1B). Similar results were observed in PCa cell
lines, that the miR-203 level was significantly decreased
in PC-3 and DU 145 cells with high metastatic potential,
in comparison to nonmalignant epithelial prostate cell
lines RWPE-1 (P < 0.05; Figure 1C). In combination,
these results indicated that the down-regulation of miR-203
in PCa may be involved in PCa progression.
MiR-203 inhibits human PCa cell proliferation, adhesion
and invasion
To investigate the biological functions of miR-203, PC-3
and DU 145 cells with ectopic expression of humanmiR-203 expression level was accessed in PCa tissues (n = 53) and
termined in metastatic and non-metastatic PCa tissues. (C) The relative
d RWPE-1 cells. The expression level of miR-203 was accessed by
< 0.01.
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human miR-203 was verified by qRT-PCR (Figure 2A).
To determine whether miR-203 regulates the malignant
behavior of PCa, we first studied the effect of miR-203
on the cell proliferation of PC-3 and DU 145 cell lines.
Our data demonstrated that the over-expression of miR-
203 significantly inhibited relative cell growth (Figure 2B).
Cancer metastasis is a multistep cascade, besides tumor
growth the adhesion-dependent migration in tissue is an-
other important prerequisite for cancer cell dissemination
[38,39]. We then explored any change in cell adhesion and
transmigration ability in PC-3 and DU 145 cells over-
expressing miR-203. The enforced expression of miR-203
attenuated cell adhesion to collagenase I and fibronectin
compared with PC-3 and DU 145 cells infected with
empty vector (Figure 2C). Similarly, in the invasion assay,
cells infected with miR-203 resulted in a significant de-
crease in invasion ability (Figure 2D).
To study the molecular mechanisms of miR-203 on
cell proliferation, adhesion and invasion, we examined
the expression of cell adhesion molecules and downstreamFigure 2 Effect of miR-203 on PCa cells and regulation of the Rac1/PA
cells after infection with miR-203 as determined by qRT-PCR. (B) Cell viabili
indicated time. (C) Cell adhesion abilities were assessed in both PC-3 and D
migration capacity was assessed in both PC-3 and DU145 cells with or with
expression of RAC-1, PAK1, p-PAK1, MEK1and p-MEK1 after the ectopic exppathways. As expected, the over-expression of miR-203
induced a marked reduction in the expression of RAC1,
p-PAK1 and p-MEK1 (Figure 2E, Additional file 1:
Figure S1), but there is no visible change in the expression
levels of total PAK1 and MEK1. These results suggested
that the inactivation of Rac-PAK signaling was a key factor.
Rap1A is up-regulated in PCa, and its expression is
inversely correlated with miR-203
To identify the potential target genes of miR-203 that
might contribute to its prometastatic function, we used
TargetScan (http://www.targetscan.org/) to predict the
targets of miR-203 and found that Rap1A was a putative
target (Figure 3A). To determine whether Rap1A was a
direct target of miR-203, reporter constructs containing
full-length Rap1A 3′-UTR were made, along with their
corresponding mutant counterpart at the miR-203 target
site. Cotransfection of the reporters with miR-203 caused
a 50% decrease in luciferase activity compared with the
control vector (Figure 3B). Mutating the miRNA bind-
ing sites on Rap1A abrogated the miRNA-mediatedK1 pathway. (A) Relative expression of miR-203 in PC-3 and DU145
ty was determined by the CCK-8 in both PC-3 and DU145 cells at the
U145 cells with or without forced expression of miR-203. (D) The
out forced expression of miR-203. (E) Western blot analysis shows the
ression of miR-203. * p < 0.05, ** p < 0.01.
Figure 3 Rap1A is a new target of miR-203. (A) The putative miR-203 binding sequence was in the 3′-UTR of Rap1A mRNA. (B) A dual luciferase
report assay was performed in HEK-293 T cells cotransfected with psi-CHECK2- Rap1A and miR-203. The dual luciferase report assay of HEK-293 T cells
cotransfected with RAP1A-3′-UTR-WT or Rap1A-3′-UTR-MUT and empty vector control or pCDH-miR-203. The Renilla luciferase activity was used as
control. (C) Western blot analysis of the endogenous expressions of Rap1A upon forced expression of miR-203. (D) The protein expression of Rap1A in
PC-3 and DU145 cells transfected with miR-203 inhibitor or NC was analyzed by western blotting. (E) Quantitative real-time PCR analysis showing the
mRNA levels of Rap1A. (F) The relative expression of Rap1A in PCa tissues and matched adjacent normal tissues was determined by qRT-PCR. (G) Plots
showing a negative correlation between the relative expression levels of miR-203 and Rap1A in the above samples. * p < 0.05, ** p < 0.01.
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These results suggested that Rap1A was a direct target of
miR-203. Rap1A protein expression was also significantly
decreased in miR-203 over-expressing cells (Figure 3C)
and Rap1A protein levels in PC-3 and DU 145 cells with
overexpression of miR-203 were increased after transfec-
tion with miR-203 inhibitor, compared with a control
miRNA inhibitor (Figure 3D). To demonstrate further that
Rap1A was negatively regulated by miR-203, we assessed
the expression of Rap1A at the mRNA level in the same
panel of specimens. The expression levels of Rap1A
mRNA were higher in cancer tissues compared with
matched adjacent non-tumor tissues (Figure 3E). An in-
verse correlation between the expression of miR-203 and
Rap1A was observed by linear regression analysis. To-
gether, these data demonstrated that that Rap1A is a dir-
ect target of miR-203. As Rap1A is reported to function as
an oncogene, this may indicate that miR-203 suppresses
tumor metastasis through inhibiting Rap1A.
Effect of knockingdown Rap1A in PCa cells
To validate whether miR-203 exerts its tumor-suppressive
function through Rap1A, we knocked down Rap1A byRNA interference techniques. The relative Rap1A protein
expression levels were significantly decreased after Rap1A
knockdown (Figure 4A). Cell viability was significantly
inhibited both in sh-Rap1A-transfected PC-3 and DU 145
cells (Figure 4B). Adhesion and invasion assays by various
extracellular matrix and matrigel invasion chambers
also showed decreased adhesion and invasion activity
(Figure 4C and D). To assess the involvement of Rap1A
on RAC1-dependent signaling, we measured rac1, p-PAK1
and p-MEK1 levels in PC-3 and DU 145 cells after Rap1A
silencing. Consistent with the results of miR-203, the pro-
tein levels of rac1, p-PAK1 and p-MEK1 were dramatically
reduced (Figure 4A, Additional file 2: Figure S2). Taken to-
gether, these results supported that Rap1A was a functional
target of miR-203 in PCa.
Over-expression of Rap1A could partly rescue the effects
of ectopic miR-203 expression in PCa cells
To further confirm a functional connection between
Rap1A and miR-203, we transfected the control vector
or a Rap1A expression vector into PC-3 and DU 145
cells stably expressing miR-203. As shown in Figure 5A,
the protein expression levels of Rap1A were significantly
Figure 4 Knockdown of Rap1A suppresses growth, adhesion and invasion of PCa cells. (A) PC-3 and DU145 cells were transfected with
shRNA for Rap1A (shRap1A) or shRNA-negative controls. The Rap1A protein was analyzed by Western blotting. Cell growth (B), cell adhesion (C),
and invasion assays (D) were performed with Rap1A silencing. * p < 0.05, ** p < 0.01.
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pression of Rap1A partly rescue adhesion and invasive-
ness enhancement of PC-3 and DU 145 cells stably
expressing miR-203 (Figure 5B and C), indicating that
over-expression of Rap1A could reverse the effects of
miR-203 in PCa cells.
MiR-203 suppresses tumor growth in vivo
To investigate the contribution of miR-203 in vivo, we
injected DU 145cells with miR-203 or control vector sub-
cutaneously into the flanks of nude mice. In this assay,
each experimental mouse bearing miR-203-overexpressing
and control vector DU 145 cells, respectively, on the rightor left dorsal thigh began to exhibit differences in tumor
growth between the two sides within two weeks, and the
difference continued to increase through the endpoint,
at which tumors of the miR-203-overexpressing group
displayed a smaller tumor size and weight (Figure 6A).
To further explore the in vivo relevance of these obser-
vations, we assessed the expression of Rap1A proteins
in homogenates from xenograft tumors. Rap1A protein
was reduced in DU 145-miR-203 cells compared with
control cells (Figure 6B). Taken together, these findings
were consistent with the in vitro results and indicated
that miR-203 has the ability to suppress PCa cell growth
in vivo.
Figure 5 Rap1A partly rescues migration and invasion inhibited by miR-203. (A) Western Blot analysis of Rap1A protein expression in PC-3
and DU 145 cells stably expressing miR-203 transfected with control vector or pCDNA-Rap1A. (B) The cell viability and the proliferation potential
of these cells were detected by CCK-8. (C) Transwell assays were performed to evaluate the invasion potential of these cells. * p < 0.05, ** p < 0.01.
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MiRNAs play important roles in a broad range of bio-
logical processes including cellular differentiation, prolifer-
ation, apoptosis, and tumor development. In the present
study, our results provided the first evidence that miR-203
supresses cell proliferation, adhesion and invasion through
targeting Rap1A in PCa.
First we verified that the expression of miR-203 was
significantly decreased in cancerous tissues of PCa pa-
tients compared with non-cancerous prostate speci-
mens. In addition, we found that miR-203 was reduced
in PCa cell lines with high metastatic potential com-
pared with the noncancerous prostate epithelial RWPE-1
cells. To further investigate the mechanisms of miR-203Figure 6 MiR-203 inhibits tumor growth in vivo. (A) Representative ana
subcutaneously with DU145 cells infected with vector or miR-203. Tumor w
in xenografts from vector control groups and miR-203 over-expression grou
from the vector control group. Lanes 2, 4, 6, 8 were samples from the miR-downregulation in PCa, we over-expressed miR-203 in
PCa cells and assessed various aspects of PCa cell biology.
Introducing miR-203 into PC-3 and DU 145 cells, which
express relatively low levels of endogenous miR-203, led
to a significant inhibition of cell proliferation, adhesion
and invasion. Data indicates that miR-203 functions as
tumor suppressor in PCa and is down-regulated in ad-
vanced PCa.
Cell adhesion and invasion both play essential roles in
tumor growth and metastasis. Then, we focused on the
targets of miR-203 which may modulate cellular adhe-
sion and invasion in the present study. Based upon bio-
informatics analysis, Rap1A was predicted as a putative
miR-203 target and the putative target sites for miR-203tomical photos of xenograft tumors in nude mice injected
eight was measured at the same time. (B) Rap1A protein expression
ps was assessed by western blot analysis. Lanes 1, 3, 5, 7 were samples
203 over-expression group. ** p < 0.01.
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the Ras family of small GTPases and was activated in re-
sponse to a number of extracellular stimuli [31]. Many
studies have shown that Rap1A was upregulated and in-
volved in cell-cell and cell-extracellular matrix adhesion
in many cancers [32-34]. By firefly luciferase activity
assay, miR-203 could reduce luciferase activity in the
Rap1A wildtype but had no effect on the mutant con-
struct. Meanwhile, the over-expression of miR-203 could
lead to a decrease of endogenous Rap1A expression in
PCa cells at both the transcriptional and translational
levels. Furthermore, miR-203 expression was inversely
correlated with Rap1A mRNA expression in PCa tissue
specimens. All these results proved Rap1A is a novel dir-
ect target of miR-203.
It is complicated to understand the biogenesis of spe-
cial miRNAs because different direct targets of certain
miRNA may play different roles in different organs and
different developmental periods. To further validate
whether miR-203 plays a tumor-suppressive role by inhibit-
ing Rap1A expression, knockdown Rap1A by shRNA-
mediated Rap1A downregulation was confirmed at protein
levels. Functional analyses were performed and found
Rap1A silencing could phenocopy the effects of miR-203
on phenotypes of PCa cells. Recent reports have shown
that the activation of Rap1A was increased in PCa and
Rap1A up-regulated the expression of integrins to pro-
mote CPa migration and invasion in vitro and in vivo [37].
Here we focused on the roles of Rap1A in cell adhesion
and invasion. We have shown that miR-203 over-
expression reduced the activation of Rac1/PAK1 pathways.
Consistent with this, we also observed inhibition of Rap1A
resulted in inactivation of Rac1/PAK1 pathways. Import-
antly, the significant effects induced by miR-203 over-
expression on cell adhesion and invasion were partially re-
versed by over-expression of Rap1A. All these proved that
Rap1A is a functional target of miR-203 and this evidence
suggested that miR-203 exerts its tumor-suppressive ef-
fects through downregulation of Rap1A in PCa cells.
Xenograft assay proved such regulation in vivo too.
Briefly, we found that Rap1A is a novel functional tar-
get of miR-203 and both over-expression of miR-203
and knockdown of Rap1A have similar effects in PCa,
which is suppressing cell proliferation, adhesion and in-
vasion through inactivation of the Rac1/PAK1 signaling
pathway. All data elucidate a new mechanism that
miR203 suppresses tumor growth through inhibiting
Rap1A. Nevertheless, additional direct target genes
mediated by miR-203 remain to be further identified in
the future.
Conclusion
In this study, our data demonstrated a previously
unrecognized mechanism that miR203 inhibits cellproliferation, adhesion and invasion through directly
targeting Rap1A. MiR-203 could be used in clinical ap-
plications for cancer therapy.
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